AstraZeneca sold the pre-existing royalty interest in Humira® (adalimumab), which AstraZeneca inherited along with the acquisition of Cambridge Antibody Technology (CAT) to Royalty Pharma. The deal could worth up to US$700 M to AstraZeneca. The analyst opinion article states that AstraZeneca had started to negotiate with Royalty Pharma for the rights to Humira® royalty stream even before it had finalized its acquisition with CAT and suggests that royalty stream acquisitions would be increasingly used to finance part or all the transactions as the big pharmas continues to buy up young biotech companies.